Equities Analysts Issue Forecasts for DAWN Q3 Earnings

Key Points

• Wedbush has increased its Q3 2025 EPS estimate for Day One Biopharmaceuticals from ($0.33) to ($0.28), maintaining an "Outperform" rating with a price target of $25.00.
• The company reported earnings of ($0.29) per share for the last quarter, exceeding analysts' estimates of ($0.35), but revenue fell short of expectations, totaling $33.91 million.
• Day One Biopharmaceuticals has seen significant institutional investment changes, with FMR LLC increasing its stake by 73.9% and other firms also boosting their positions recently.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Analysts at Wedbush upped their Q3 2025 EPS estimates for Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, August 5th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.28) for the quarter, up from their prior forecast of ($0.33). Wedbush has a "Outperform" rating and a $25.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.19) EPS, Q1 2026 earnings at ($0.26) EPS, Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.14) EPS and FY2027 earnings at ($0.56) EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. Day One Biopharmaceuticals had a negative return on equity of 19.01% and a negative net margin of 50.63%. The company had revenue of $33.91 million during the quarter, compared to analyst estimates of $35.55 million.

Other analysts have also issued research reports about the company. HC Wainwright dropped their price target on Day One Biopharmaceuticals from $36.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Needham & Company LLC dropped their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $25.33.

Day One Biopharmaceuticals Stock Performance

DAWN stock traded up $0.19 on Friday, reaching $6.09. The company's stock had a trading volume of 2,050,864 shares, compared to its average volume of 1,374,569. The business has a fifty day simple moving average of $6.67 and a two-hundred day simple moving average of $7.94. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $16.76. The firm has a market cap of $623.29 million, a PE ratio of -6.42 and a beta of -1.26.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC purchased a new position in Day One Biopharmaceuticals in the first quarter worth about $88,000. Rhumbline Advisers raised its holdings in Day One Biopharmaceuticals by 8.3% in the first quarter. Rhumbline Advisers now owns 81,844 shares of the company's stock worth $649,000 after buying an additional 6,291 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Day One Biopharmaceuticals by 12.4% in the fourth quarter. MetLife Investment Management LLC now owns 34,248 shares of the company's stock worth $434,000 after buying an additional 3,781 shares during the last quarter. Millennium Management LLC raised its holdings in Day One Biopharmaceuticals by 80.4% in the fourth quarter. Millennium Management LLC now owns 192,100 shares of the company's stock worth $2,434,000 after buying an additional 85,606 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in Day One Biopharmaceuticals by 23.5% in the fourth quarter. ProShare Advisors LLC now owns 19,394 shares of the company's stock worth $246,000 after buying an additional 3,687 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 4,282 shares of the firm's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $26,805.32. Following the completion of the transaction, the chief financial officer owned 265,231 shares of the company's stock, valued at approximately $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Adam Dubow sold 4,552 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $28,495.52. Following the completion of the transaction, the general counsel directly owned 47,136 shares of the company's stock, valued at approximately $295,071.36. This represents a 8.81% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,725 shares of company stock valued at $167,299. 6.20% of the stock is currently owned by company insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.